and then next week is the last week where the company will trade in the dark (like RP11 patients) re the outcome of therapy administered to the various cohorts. There are several different combos and times of admin and apparently all have asked to continue on the drug which requires intra ocular injection every 2?months or so.
If indeed there is a clear divergence from the non treated eye and group and the divergence continues to widen as time goes forward then a revenue of close to a $!B US is achievable sometime down the track.
If half of that is probable then that should raise the mcap to over a billion even this far out from revenue.
Of course, there are 3 other drugs bringing up the rear with even greater prospects so I think we may have seen prices below the recent cap raise for the very last time.
PYC Price at posting:
$1.12 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)